CytRx Corporation (CYTR)
Stock Price:
$0.580 USD
0.010 (1.81%)
Updated Oct 20, 2020 2:16 PM EDT - Market closed
Key Info
| Market Cap |
19.52M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-6.98M |
| Shares Out |
33.64M |
| EPS (ttm) |
-0.21 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 20, 2020 |
| Last Price |
$0.580 |
| Previous Close |
$0.570 |
| Change ($) |
0.010 |
| Change (%) |
1.81% |
| Day's Open |
0.570 |
| Day's Range |
0.561 - 0.660 |
| Day's Volume |
89,044 |
| 52-Week Range |
0.23 - 0.847 |
More Stats
| Market Cap |
19.52M |
| Enterprise Value |
5.61M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
33.64M |
| Float |
28.01M |
| EPS (basic) |
-0.20 |
| EPS (diluted) |
-0.21 |
| FCF / Share |
-0.14 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
294,308 |
| Short Ratio |
1.96 |
| Short % of Float |
1.05% |
| Beta |
1.77 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
1.72 |
| Revenue |
n/a |
| Operating Income |
-7.20M |
| Net Income |
-6.98M |
| Free Cash Flow |
-4.79M |
| Net Cash |
13.91M |
| Net Cash / Share |
0.41 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-25.29% |
| ROE |
-44.96% |
| ROIC |
-397.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
4.50
Current: $0.580
High
4.50
Target: 4.50
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | 0.25 | 0.10 | 0.20 | 0.10 | 0.10 | 0.30 | 0.10 | 0.25 | 0.10 |
| Revenue Growth | - | 150% | -50% | 100% | 0% | -66.67% | 200% | -60% | 150% | - |
| Gross Profit | - | 0.25 | 0.10 | 0.20 | 0.10 | 0.10 | 0.30 | 0.10 | 0.25 | 0.10 |
| Operating Income | -7.86 | -8.25 | -28.36 | -52.26 | -63.28 | -49.61 | -27.59 | -21.05 | -22.65 | -16.75 |
| Net Income | -7.16 | -12.71 | -34.99 | -50.77 | -58.59 | -30.12 | -47.49 | -17.96 | -14.42 | 0.41 |
| Shares Outstanding | 33.26 | 30.95 | 24.04 | 13.51 | 10.08 | 9.06 | 5.48 | 3.83 | 2.99 | 2.61 |
| Earnings Per Share | -0.22 | -0.41 | -1.46 | -3.78 | -5.82 | -3.30 | -8.64 | -4.68 | -4.80 | 0.18 |
| Operating Cash Flow | -5.72 | -10.87 | -27.10 | -49.85 | -47.58 | -40.56 | -23.75 | -19.04 | -16.67 | -14.54 |
| Capital Expenditures | 0.48 | -0.01 | -0.13 | -1.02 | -0.33 | -0.96 | -0.04 | -0.14 | -0.05 | -0.32 |
| Free Cash Flow | -5.24 | -10.88 | -27.24 | -50.87 | -47.91 | -41.51 | -23.79 | -19.19 | -16.72 | -14.86 |
| Cash & Equivalents | 16.13 | 21.37 | 37.50 | 56.96 | 57.30 | 77.84 | 38.57 | 38.34 | 36.05 | 26.89 |
| Total Debt | 0.07 | - | 10.60 | 23.97 | - | - | - | - | - | - |
| Net Cash / Debt | 16.06 | 21.37 | 26.90 | 32.99 | 57.30 | 77.84 | 38.57 | 38.34 | 36.05 | 26.89 |
| Assets | 17.26 | 22.93 | 48.35 | 62.77 | 67.02 | 85.69 | 41.50 | 40.23 | 37.85 | 36.70 |
| Liabilities | 2.05 | 2.56 | 30.20 | 37.99 | 22.95 | 17.78 | 30.84 | 10.07 | 13.60 | 6.13 |
| Book Value | 15.20 | 20.36 | 18.15 | 24.78 | 44.08 | 67.91 | 10.66 | 30.17 | 24.25 | 30.57 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
CytRx Corporation |
| Country |
United States |
| Employees |
4 |
| CEO |
Steven A. Kriegsman |
Stock Information
| Ticker Symbol |
CYTR |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: CYTR |
| IPO Date |
November 10, 1986 |
Description
CytRx Corporation, a biopharmaceutical company, engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company's lead candidates include linker activated drug release (LADR) -7, LADR-8, LADR-9, and LADR-10; and Aldoxorubicin, a conjugate of prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and to concentrate the drug at the site of the tumor. It also provides albumin companion diagnostic for cancer. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.